Targeting difficult antigens
Our modular vaccine technology builds on a species-specific generic section coupled with the specific antigen. This allows the CD32-mediated triggering of plasmacytoid dendritic cells (pDCs) to produce large amounts of Th1-inducing cytokines through a specific interaction with the Toll Like Receptor 9 (TLR9), which therefore serves as intrinsic “adjuvant”. The vaccine antigen can be peptides, neoantigens and proteins, all are able to activate antigen-specific T and B cells depending on the design.
The technology has been shown in vivo to work with tumor related antigens and allergens in a most-effective way, i.e. fast onset of a dose-dependent immune response with extremely high titers.